- Home
- TSI vs KPTI Comparison
TSI vs KPTI Comparison
Compare TSI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | KPTI |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.7M | 194.8M |
| IPO Year | 1995 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TSI | KPTI |
|---|---|---|
| Price | $4.40 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 126.4K | ★ 567.0K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $4.39 | $3.65 |
| 52 Week High | $5.06 | $10.99 |
Technical Indicators
Market Signals| Indicator | TSI | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 15.14 |
| Support Level | N/A | N/A |
| Resistance Level | $4.58 | $6.96 |
| Average True Range (ATR) | 0.03 | 0.73 |
| MACD | -0.00 | -0.49 |
| Stochastic Oscillator | 6.25 | 3.58 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).